REMARKS

Consideration of the above-captioned application in view of the above amendments and following remarks is requested. Claims 8, 9, 11-13, 15, 18-23 and 28-41 are now in the case. Claims 1-7, 10, 14, 16-17, and 24-27 have been canceled. Claims 8, 9, 11-13, 15, 18-23 have been amended. Claims 28-41 are newly added. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made".

On the basis of the above amendments and remarks, Applicants believe that the claims are in condition for allowance. Applicants believe that no new matter has been added. Applicants reserve the right to prosecute the original claims in another continuing application. Consideration of the application and its allowance are requested. If for any reason the Examiner feels that a telephone conference would expedite prosecution of the application, the Examiner is invited to telephone the undersigned at (206) 442-6752.

Respectfully Submitted,

Robyn adam

Robyn Adams

Registration No. 44,495

Enclosures:

Express Mail Certificate

Request for filing under 37 C.F.R. §1.53(b): Application and fee

Transmittal (in duplicate)

Letter regarding Computer Readable Sequence Listing

Postcard

Version with Markings to Show Changes Made

15/2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 1-7, 10, 14, 16-17, 24-27 have been canceled.

Claims 8, 9, 11-13, 15, 18-23 have been amended as follows:

- 8. (Amended) An isolated polynucleotide molecule encoding a polypeptide molecule, wherein the polypeptide molecule comprises a contiguous sequence of [14] 13 amino acids of SEQ ID NO:2, wherein the contiguous sequence comprises residues at positions 443 to 445 of SEQ ID NO:2, and wherein the polypeptide binds an integrin.
- 9: (Amended) An isolated polynucleotide molecule [according to claim 8] encoding a polypeptide molecule, wherein the polypeptide molecule comprises residues 437 to 450 of SEQ ID NO:2.
- 11. (Amended) An isolated polynucleotide molecule [according to claim 10] encoding a polypeptide molecule, wherein the polypeptide molecule [is] comprises residues 164 to 382 of SEQ ID NO:2.
- 12. (Amended) An isolated polynucleotide molecule [according to claim 10] encoding a polypeptide molecule, wherein the polypeptide molecule [is] comprises residues 383 to 464 of SEQ ID NO:2.
- 13. (Amended) An isolated polynucleotide molecule [according to claim 10] encoding a polypeptide molecule, wherein the polypeptide molecule [is] comprises residues 465 to 696 of SEQ ID NO:2.
- 15. (Amended) An isolated polynucleotide encoding a fusion protein having a first segment and a second segment, wherein the first segment comprises [a first polypeptide encoding] a polypeptide having a protease domain and the second segment comprises [a second polynucleotide encoding] a polypeptide that has a contiguous sequence of [14] 13 amino acids between residues 383 and 464 of SEQ ID NO:2, [and] wherein the first segment is positioned amino-terminally to the second segment, and wherein the protein binds an integrin.

- 5/2001
- 18. (Amended) [An] <u>The</u> isolated polynucleotide molecule according to claim [17] <u>12</u>, wherein the [polynucleotide] <u>polypeptide</u> molecule [is selected from the group consisting of:
- a) a polynucleotide molecule that encodes a polypeptide molecule that is at least 80 % identical to] <u>comprises</u> residues 383 to 696 of SEQ ID NO:2[; and
 - b) a polynucleotide molecule that is complementary to a)].
- 19. (Amended) [An] <u>The</u> isolated polynucleotide molecule according to claim [17] <u>18</u>, wherein the [polynucleotide] <u>polypeptide</u> molecule [is selected from the group consisting of:
- a) a polynucleotide molecule that encodes a polypeptide molecule that is at least 80 % identical to] <u>comprises</u> residues 1 to 696 of SEQ ID NO:2[; and
 - b) a polynucleotide molecule that is complementary to a)].
- 20. (Amended) An expression vector comprising the following operably linked elements:
 - a) a transcription promoter;
- b) a DNA segment [encoding the polypeptide of claim 1] comprising the polynucleotide according to claim 12; and
 - c) a transcription terminator.
- 21. (Amended) [An] <u>The</u> expression vector of claim 20 wherein the DNA segment further encodes an affinity tag.
- 22. (Amended) A cultured cell into which has been introduced [an] the expression vector according to claim [21] 20, wherein said cell expresses the polypeptide encoded by the DNA segment.
- 23. (Amended) A method of producing a polypeptide comprising culturing [a] the cell according to claim 22, whereby said cell expresses the polypeptide encoded by the DNA segment; and recovering the polypeptide.

Claims 28-41 have been added.